Copy to clipboard 
Medartis reported 1H23 orthopedic sales of CHF 103.3 million ($112.6 million), +16.8% compared to the first half of 2022.
The company achieved strong performances in EMEA and the U.S. While all of Medartis’ European markets contributed, Germany accounted for a third of all regional growth during the half. Slightly offsetting this strength, mild winters in France and Switzerland contributed to softer demand for trauma products. In the U.S., portfolio expansion, higher sales rep productivity and onboarding new reps drove growth in that market.
Performance in APAC was mixed, as government-implemented price adjustments impacted implants. However, Medartis’ Japanese subsidiary grew its volume by 15% during the half. Dynamic growth in Mexico and Brazil led the Latin American region.
Within its trauma business, the company saw strength in the ankle and forefoot for lower extremities. Shoulder, hand and wrist all achieved healthy growth in upper extremities. Within this category, Medartis is focused on penetrating geographies with little share.
The company experienced an IT attack in May, which impacted first-half growth by approximately three percentage points. Given performance to date and current trends, Mediartis reaffirmed its 2023 guidance for organic sales growth in the range of 15% to 18%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $91.4 | $81.2 | $10.2 | 12.6% |
| Other | $21.2 | $15.3 | $5.9 | 38.9% |
| Total | $112.6 | $96.4 | $16.2 | 16.8% |
Orthopedic Sales by Geography
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $27.8 | $20.0 | $7.8 | 39.2% |
| OUS | $84.8 | $76.4 | $8.4 | 11% |
| EMEA | $56.1 | $49.5 | $6.7 | 13.5% |
| APAC | $17.2 | $17.3 | ($0.1) | (0.6%) |
| ROW | $11.4 | $9.6 | $1.8 | 18.9% |
| Total | $112.6 | $96.4 | $16.2 | 16.8% |
Medartis reported 1H23 orthopedic sales of CHF 103.3 million ($112.6 million), +16.8% compared to the first half of 2022.
The company achieved strong performances in EMEA and the U.S. While all of Medartis' European markets contributed, Germany accounted for a third of all regional growth during the half. Slightly offsetting this strength,...
Medartis reported 1H23 orthopedic sales of CHF 103.3 million ($112.6 million), +16.8% compared to the first half of 2022.
The company achieved strong performances in EMEA and the U.S. While all of Medartis’ European markets contributed, Germany accounted for a third of all regional growth during the half. Slightly offsetting this strength, mild winters in France and Switzerland contributed to softer demand for trauma products. In the U.S., portfolio expansion, higher sales rep productivity and onboarding new reps drove growth in that market.
Performance in APAC was mixed, as government-implemented price adjustments impacted implants. However, Medartis’ Japanese subsidiary grew its volume by 15% during the half. Dynamic growth in Mexico and Brazil led the Latin American region.
Within its trauma business, the company saw strength in the ankle and forefoot for lower extremities. Shoulder, hand and wrist all achieved healthy growth in upper extremities. Within this category, Medartis is focused on penetrating geographies with little share.
The company experienced an IT attack in May, which impacted first-half growth by approximately three percentage points. Given performance to date and current trends, Mediartis reaffirmed its 2023 guidance for organic sales growth in the range of 15% to 18%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. We estimate orthopedic sales and growth on an as-reported basis.
Orthopedic Sales by Segment
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $91.4 | $81.2 | $10.2 | 12.6% |
| Other | $21.2 | $15.3 | $5.9 | 38.9% |
| Total | $112.6 | $96.4 | $16.2 | 16.8% |
Orthopedic Sales by Geography
| 1H23 | 1H22 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $27.8 | $20.0 | $7.8 | 39.2% |
| OUS | $84.8 | $76.4 | $8.4 | 11% |
| EMEA | $56.1 | $49.5 | $6.7 | 13.5% |
| APAC | $17.2 | $17.3 | ($0.1) | (0.6%) |
| ROW | $11.4 | $9.6 | $1.8 | 18.9% |
| Total | $112.6 | $96.4 | $16.2 | 16.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
